Clinical Trial · NCT03334500

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer

Overview

Men with a history of prostate cancer may be in this study. Subjects recommended for a prostatectomy or oligometastectomy will undergo PET/CT imaging using a novel radiotracer \[18F\]FTT to evaluate PARP-1 activity in known or suspected sites of primary or metastatic disease. Imaging will be compared with pathology results, including additional research assays when possible.

Sponsor

Abramson Cancer Center of the University of Pennsylvania

Phase

Early Phase 1

Contacts

Dan Pryma, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT03334500

Drug / Compound

FTT

Isotope(s):

Target(s):

PARP

Ligand Class: Small Molecules

Eligibility

Inclusion

At least one lesion that is 1 cm or greater in size by standard imaging (e.g. ultrasound, MRI, CT). Only one type of imaging is required to show a lesion of 1 cm or greater in order for the patient to be eligible to participate in this study.
Must meet one of the following criteria:
Willing to allow use or collection of pathology tissue for the purposes of research from either clinical biopsy or surgical procedure (if adequate tissue is available)
At least two tissue cores containing at least 50% tumor (per pathology report) OR
Biopsy proven prostate cancer
Recommended for clinically indicated radical prostatectomy or oligometastectomy

Exclusion

Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.
Inability to tolerate imaging procedures in the opinion of an investigator or treating physician